Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Completed · Phase 2 · Has a placebo group

Conditions studied: Psoriasis Vulgaris

In brief

The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.

Key facts

Study ID

NCT01465282

Run by

Creabilis SA

People needed

160

Starts

2011-12-01

Expected to finish

2012-09-01

Last updated by the study team

2013-03-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects aged at least 18 years.
• Stable psoriasis vulgaris

You may not qualify if…

• Subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.

Where it is running

• Study site — Hotsprings, Arkansas, United States
• Study site — San Ramon, California, United States
• Study site — Bay City, Michigan, United States
• Study site — Fridley, Minnesota, United States
• Study site — South Euclid, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — San Antonio, Texas, United States
• Study site — Spanish Fork, Utah, United States
• Study site — Birmingham, United Kingdom
• Study site — Cardiff, United Kingdom
• Study site — Glasgow, United Kingdom
• Study site — Manchester, United Kingdom
• Study site — Merseyside, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.